Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. Replacing failed nerve terminals.
Freed
C R
CR
Department of Medicine, University of Colorado School of Medicine, Denver 80262.
Breeze
R E
RE
Rosenberg
N L
NL
Schneck
S A
SA
D000978:Antiparkinson Agents / Q000008:administration & dosage; D016380:Brain Tissue Transplantation / Q000502:physiology*; D002421:Caudate Nucleus / Q000503:physiopathology / Q000601:surgery; D003131:Combined Modality Therapy; D004292:Dominance, Cerebral / Q000502:physiology; D004298:Dopamine / Q000502:physiology*; D005260:Female; D016332:Fetal Tissue Transplantation / Q000502:physiology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009416:Nerve Regeneration / Q000502:physiology*; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000503:physiopathology / Q000601:surgery*; D011699:Putamen / Q000503:physiopathology / Q000601:surgery; D011954:Receptors, Dopamine / Q000502:physiology*
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D004298:Dopamine